<DOC>
	<DOCNO>NCT00719420</DOCNO>
	<brief_summary>More half world 's population infect Helicobacter pylorus , bacterium colonizes human stomach . Although infected subject live free symptom disease outcome ( except superficial gastritis ) , develop peptic ulcer gastric cancer , others may develop non-ulcer dyspepsia . Current clinical practice management peptic ulcer disease include test treat H. pylorus , present . Although triple therapy contain 2 antibiotic plus bismuth compound , proton-pump inhibitor , H2-receptor antagonist effective eliminate H. pylorus Europe North America , treatments dramatically less effective develop country . Our recent meta-analysis show quadruple therapy contain clarithromycin , amoxicillin , metronidazole proton pump inhibitor effective presence clarithromycin metronidazole resistance . However , regimen yet test develop country . Therefore , current randomize clinical trial Pasto , Colombia , aim examine effectiveness clarithromycin , amoxicillin , metronidazole without proton pump inhibitor compare Food Drug Administration approve 10-day regimen contain clarithromycin , amoxicillin omeprazole . Since antibiotic therapy effective within specific gastric pH range , since mutifocal atrophy result damage loss acid produce parietal cell , test efficacy modify therapy stratify diagnosis multifocal atrophic gastritis .</brief_summary>
	<brief_title>Clarithromycin , Amoxicillin , Metronidazole Based Regimens Treat Helicobacter Pylori Infections Colombia</brief_title>
	<detailed_description>Warren Marshall 's Noble prize win discovery Helicobacter pylorus , subsequent work show gastritis peptic ulcer could successfully treat eradicate bacterium , ultimately revolutionized physician treat peptic ulcer disease . However , previous research show treatment H. pylori dramatically less effective presence drug resistance , especially develop country , H. pylori highly prevalent . Our recent meta-analysis , prompt Canadian Helicobacter Consensus Group change treatment guideline Canada , show quadruple therapy clarithromycin , amoxicillin , metronidazole ( CAM ) proton pump inhibitor effective presence clarithromycin metronidazole resistance . However , regimen yet test develop country . Since Warren Marshall 's discovery , H pylorus also implicate risk factor gastric cancer possibly non-ulcer dyspepsia ( NUD ) , conflict evidence suggests may protective factor disease outcomes esophagus . Glandular atrophy cause H. pylorus believe initiate precancerous process disrupt mucus barrier , allow carcinogen direct contact gastric cell . Atrophy follow increase pH gastric cavity . Carcinogens , epithelium mutation , rapid cell turnover , toxin , virulence factor H. pylorus strain contain CagA vacuolating cytotoxin ( VacA ) proteins , cagA vacA gene encode protein , putative risk factor progression intestinal metaplasia , follow dysplasia , invasive carcinoma . Much debate exist whether anti H. pylorus treatment benefit infected subject non-ulcer dyspepsia . A meta-analysis short-term trial suggest H. pylorus weak risk factor dyspepsia unidentified population . This information together cost-effectiveness analysis result European Maastricht 2-2000 Consensus recommendation young patient persistent dyspepsia test , infect , treat H. pylorus ( 'the test-and-treat strategy ' ) . Nevertheless , without strong evidence support strategy dyspepsia , devoid understand H. pylori elimination affect symptom , strategy gain wide spread acceptance part current standard care many country . However , study examine effect H. pylorus symptom develop country , infection occur , lack . Although gastric cancer rate decline developed country , high rate observe minority immigrant group , still 2nd frequent cancer worldwide . In Nariño , Colombia , incidence gastric cancer estimate high world rate 150/100,000/yr . In 1993-94 conducted randomize clinical trial aim short-term reduction inflammation epithelial damage stomach H. pylorus infect subject NUD general population Pasto , capital Nariño ( `` Pasto cohort '' ) . Data trial subsequent meta-analysis show classical anti-H. pylorus treatment effectively eliminate H. pylorus Europe North America , effective population Pasto high prevalence infection high prevalence metronidazole resistance . We test efficacy promising 14-day clarithromycin- , amoxicillin- metronidazole- ( CAM ) triple quadruple base regimens eradication compare FDA recommend 10-day regimen ( clarithromycin , amoxicillin , omeprazole ) . Since antibiotic therapy effective within specific gastric pH range , since mutifocal atrophy result damage loss acid produce parietal cell , test efficacy modify therapy stratify diagnosis multifocal atrophic gastritis . We hypothesize : 1 ) among H. pylorus infected subject Pasto cohort multifocal atrophic gastritis , randomize 14-day triple therapy CAM likely eradicate H. pylorus infection compare randomized FDA approve regimen ; 2 ) among H. pylorus infected subject Pasto cohort without multifocal atrophic gastritis , randomize 14-day quadruple therapy CAM plus omeprazole , likely eradicate H. pylorus infection compare randomized FDA approve regimen ; 3 ) among H. pylorus infected subject Pasto without previous histological diagnosis , randomize 14-day CAM therapy likely eradicate H. pylorus compare randomized FDA approve regimen . Therefore , primary aim conduct randomize clinical trial Pasto , Colombia assess diagnosis-specific efficacy 14-day CAM triple therapy , 14-day clarithromycin , amoxicillin , metronidazole omeprazole quadruple therapy eliminate H. pylorus compare FDA approve 10-day clarithromycin , amoxicillin , omeprazole triple therapy subject never treat H pylori infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Aged 2977 year ; live Pasto , Colombia least 5 year plan remain Pasto ≥5 year ; Currently Helicobacter pylorus infection ; Willing refrain alcohol consumption 2 week ; Have never take therapy eradicate Helicobacter pylorus ; Have take antibiotic , bismuth compound , protonpump inhibitor , H2receptor antagonists , antacid within 30 day trial ; Are pregnant , little risk pregnancy . History kidney , liver , heart , mental disease ; Frequent alcohol consumption ; Allergic clarithromycin , amoxicillin , penicillin , omeprazole metronidazole ; Currently take drug may interact trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Randomized clinical trial</keyword>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>clarithromycin</keyword>
	<keyword>metronidazole</keyword>
	<keyword>amoxicillin</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>Colombia</keyword>
</DOC>